Adverse events associated with drug‐related thiamine deficiency: A pharmacovigilance study
Mit Arzneimitteln verbundene Thiaminmangel-Ereignisse: pharmakovigilanzbasierte Studie
Journal of Parenteral and Enteral Nutrition · 2026-07 · 50 (5) · 727-735
DOI: 10.1002/jpen.70085 ↗Auf einen Blick
In der US-Datenbank wurden 1.046 Fälle von Thiaminmangel erfasst. 38 Arzneimittel zeigten konsistent positive Sicherheits-Signale; häufig genannt wurden Furosemid und Metformin.
Fragestellung
Welche unerwünschten Ereignisse sind in der FAERS-Datenbank mit arzneimittelbedingtem Thiaminmangel assoziiert?
Methode
Pharmakovigilanzstudie mit Auswertung der FDA Adverse Event Reporting System-Daten von 2004 bis 2024; Signalprüfung mit vier Algorithmen.
Ergebnisse
1.046 Fälle von Thiaminmangel, 46,0 % Hospitalisationen. Medianes Alter 55,0 Jahre (IQR 41,0–68,0), 42,5 % weiblich. 38 Arzneimittel zeigten in allen 4 Methoden positive Signale.
Schlussfolgerung der Autor:innen
Die Analyse identifiziert Sicherheits-Signale für einen Zusammenhang bestimmter Medikamente mit Thiaminmangel und unterstreicht die klinische Wachsamkeit sowie die Berücksichtigung eines Thiamin-Monitorings bei Risikopatient:innen.
Kernaussagen
- 1.046 gemeldete Fälle von Thiaminmangel
- 38 Arzneimittel mit konsistent positiven Signalen
- Häufig genannt: Furosemid, Metformin, Fedratinib, Metronidazol, Fluorouracil
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parenteral and Enteral Nutrition, online erschienen am 21.03.2026. Verfasst von Xiaolang Du und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Cancer Prevention and Therapy, Department of Pharmacy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Ce…. Hauptthemen laut MEDLINE: Thiamine Deficiency, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Tianjin Key Medical Discipline Construction Project (Grant No.TJYXZDXK-3-003A).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Thiamine deficiency can cause severe complications, including beriberi, Wernicke's encephalopathy, and Korsakoff syndrome, potentially leading to irreversible neurological damage or death. While causes such as chronic alcohol use disorder are established, drug‐induced thiamine deficiency represents a potential risk that is often overlooked. However, systematic data on this association remain limited.
Methods
We utilized relevant preferred terms from the Medical Dictionary for Regulatory Activities to identify adverse events in the United States Food and Drug Administration Adverse Event Reporting System from 2004 through 2024. Signal detection was performed using four algorithms: the reporting odds ratio, the proportional reporting ratio, the information component, and the empirical Bayes geometric mean.
Results
We identified 1,046 cases of thiamine deficiency, showing an increasing trend. Hospitalization was reported in 46.0% of cases. The median patient age was 55.0 years (interquartile range: 41.0–68.0), and 42.5% were female. Healthcare professionals submitted 81.5% of reports, and the United States contributed the largest share (27.8%). The five agents most frequently reported were furosemide, metformin, fedratinib, metronidazole, and fluorouracil. Overall, 38 drugs demonstrated consistently positive safety signals across all four methods. Additional drugs exhibiting notable signals included arsenic trioxide, torasemide, rabeprazole, and hydrochlorothiazide.
Conclusion
This pharmacovigilance analysis identifies safety signals linking specific medications with thiamine deficiency, potentially mediated by mechanisms such as transport inhibition and metabolic interference. These findings highlight the importance of clinical vigilance and the consideration of thiamine monitoring in high‐risk patients to mitigate the risk of neurological complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Cancer Prevention and Therapy, Department of Pharmacy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospi…
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, School of Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science an…
- School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xiaolang Du, Zengguang Ma
Förderung
- Tianjin Key Medical Discipline Construction Project (Grant No.TJYXZDXK-3-003A)
Zitieren
APA
Du, X., Wang, W., Ma, Z., & Zhou, X. (2026). Adverse events associated with drug‐related thiamine deficiency: A pharmacovigilance study. Journal of Parenteral and Enteral Nutrition, 50(5), 727-735. https://doi.org/10.1002/jpen.70085
Vancouver
Du X, Wang W, Ma Z, Zhou X. Adverse events associated with drug‐related thiamine deficiency: A pharmacovigilance study. Journal of Parenteral and Enteral Nutrition. 2026;50(5):727-735. doi:10.1002/jpen.70085
BibTeX
@article{Du2026,
author = {Du, Xiaolang and Wang, Wenhua and Ma, Zengguang and Zhou, Xin},
title = {Adverse events associated with drug‐related thiamine deficiency: A pharmacovigilance study},
journal = {Journal of Parenteral and Enteral Nutrition},
year = {2026},
volume = {50},
number = {5},
pages = {727--735},
doi = {10.1002/jpen.70085}
}
EUVIMED